Investigators reviewed cases of patients with multiple sclerosis treated with alemtuzumab to determine the type and frequency of thyroid dysfunction.
First trimester exposure to anytithyroid drugs was associated with a greater risk of congenital malformations, especially for pregnant women who were given prescriptions for methimazole or both methimazole and propylthiouracil.
Patients given teprotumumab were more likely to experience a response at 24 weeks vs placebo.
In a randomized, double-blind study, Rituximab was more effective in treating Graves' orbitopathy than intravenous methylprednisolone.
Statins and thyroidectomy may delay or prevent thyroid-associated ophthalmopathy in Graves' disease.
Thyroid-specific autoantibody levels did not predict clinical features of Graves' disease, including ophthalmopathy or goiter.
Women should likely discontinue methimazole during pregnancy to prevent complications.
Rituximab did not perform better than a placebo in treating Graves' orbitopathy in a randomized controlled trial.
Endocrinology Advisor Articles
- Heritability of BMI Stronger in Obesogenic Environments
- Adverse Events Associated With Diazoxide Treatment for Congenital Hyperinsulinism
- Maternal Gluten Intake Associated With Risk for Type 1 Diabetes in Offspring
- Patterns of Evidence-Based Diabetes Interventions at Local Health Departments
- Bone-Derived Factors in the Treatment of Diabetes
- Vitamin D Supplementation Has No Effect on Musculoskeletal Health
- Deep Learning Algorithm Efficiently Detects Vision-Threatening Diabetic Retinopathy
- Industry-Funded Trials Often Involve Employees in Studies
- Nutrition Tips for Physicians: Staying Healthy During Busy Days
- Early-Onset Asthma/Wheezing Associated With Later Childhood Obesity